MARCELO ARAUJO QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject PET/MR characterization of mucinous versus nonmucinous components of rectal adenocarcinoma: a comparison of tumor metabolism and cellularity(2018) QUEIROZ, M.; BARBOSA, F. G.; NAVES, A.; DREYER, P.; MARIN, J. G.; ORTEGA, C.; CERRI, G. G.; BUCHPIGUEL, C.conferenceObject Clinical workflow of PET/MR for primary staging of rectal cancer(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; CERRI, G. G.; BUCHPIGUEL, C.conferenceObject PET/CT for primary staging of rectal cancer patients with and without extramural vascular invasion detected by MR (EMVI-MR)(2016) QUEIROZ, M.; ORTEGA, C.; MORITA, T.; VIANA, P.; ZAGATTI, M.; BLASBALG, R.; MENEZES, M.; BUCHPIGUEL, C.- An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases(2021) HUSSEINI, Jad S.; AMORIM, Barbara Juarez; TORRADO-CARVAJAL, Angel; PRABHU, Vinay; GROSHAR, David; UMUTLU, Lale; HERRMANN, Ken; CANAMAQUE, Lina Garcia; GARZON, Jose Ramon Garcia; PALMER, William E.; HEIDARI, Pedram; SHIH, Tiffany Ting-Fang; SOSNA, Jacob; MATUSHITA, Cristina; CERCI, Juliano; QUEIROZ, Marcelo; MUGLIA, Valdair Francisco; NOGUEIRA-BARBOSA, Marcello H.; BORRA, Ronald J. H.; KWEE, Thomas C.; GLAUDEMANS, Andor W. J. M.; EVANGELISTA, Laura; SALVATORE, Marco; CUOCOLO, Alberto; SORICELLI, Andrea; HEROLD, Christian; LAGHI, Andrea; MAYERHOEFER, Marius; MAHMOOD, Umar; CATANA, Ciprian; DALDRUP-LINK, Heike E.; ROSEN, Bruce; CATALANO, Onofrio A.Background MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. Methods We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. Results Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. Conclusion PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.
- Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment(2019) COSTA, Larissa Bastos; QUEIROZ, Marcelo Araujo; BARBOSA, Felipe de Galiza; NUNES, Rafael Fernandes; MARIN, Jose Flavio Gomes; DZIK, Carlos; BUCHPIGUEL, Carlos Alberto
- Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients(2021) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.Purpose We compared the diagnostic accuracy of detecting distant metastases for baseline rectal cancer staging between PET/MRI and conventional staging (CS). Materials and methods This prospective study from November 2016 to April 2018 included 101 rectal adenocarcinoma patients for primary staging. These patients underwent whole-body PET/MRI in addition to CS (pelvic MRI and thoracic and abdominal contrast-enhanced CT). Different readers analyzed CS and PET/MRI findings for primary tumor, nodal, and metastatic staging. The presence, number, and location of metastases were recorded according to the organ involved (non-regional lymph nodes (LNs), liver, lungs, or others). Lesions were defined as positive, negative, or indeterminate. The number of lesions per organ was limited to 10. The McNemar test was used to compare the accuracies. Results PET/MRI exhibited a higher accuracy in detecting metastatic disease than CS in all patients (88.4% vs. 82.6%,p = 0.003) and in patients with extramural vascular invasion (EMVI) (88.9% vs. 85.5%,p = 0.013). The detection rate of PET/MRI was superior to that of CS for all lesions [84.1% vs. 68.9%,p = 0.001], as well as those in the liver (89.2% vs. 84.2%), non-regional LNs (90.0% vs. 36.7%), and lungs (76.4% vs. 66.9%). PET/MRI correctly classified 19/33 (57.5%) patients with indeterminate lesions on CS. Conclusion PET/MRI yields higher accuracy than CS for detecting distant synchronous metastases in the baseline staging of patients with rectal cancer and EMVI. PET/MRI exhibited a higher detection rate than CS for identifying non-regional LNs, hepatic lesions, and pulmonary lesions as well as correctly classifying patients with indeterminate lesions.
conferenceObject PET/MR for staging rectal cancer: a comparison to conventional staging with pelvic MR and thoracoabdominal CT(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; BLASBALG, R.; NAHAS, S.; CERRI, G. G.; BUCHPIGUEL, C.conferenceObject Diagnostic performance of PET/MR in identifying high-risk primary rectal cancer patients(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; BLASBALG, R.; CERRI, G. G.; BUCHPIGUEL, C.